About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

MEOI and HRQoL in CLL Patients Treated With BTKis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04938141

MEOI and HRQoL in CLL Patients Treated With BTKis

This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Br...

Lead sponsor: AstraZeneca•16 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•≥18 years old
•Physician-confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
•BTKi naïve patients who initiate acalabrutinib or ibrutinib treatment alone or in combination with an anti-CD20 mAb within 7 days (before or after) study enrollment\*. Both treatment naïve and relapsed/refractory CLL patients will be included.
•Provides informed consent
•Adequate English reading skills
•Able to access and use a computer, tablet, or smartphone to complete PROs

Exclusion Criteria

•Use of BTKi any time prior to study enrollment.
•Currently receiving systemic treatment for another malignancy
•Currently enrolled in a clinical trial

Related studies

RECRUITINGPhase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

RECRUITINGPhase 2

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more

RECRUITINGPhase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

RECRUITINGPhase 1/2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731 · B-cell Malignancy, Non-Hodgkin Lymphoma, and more

RECRUITINGPhase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 21, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment23

Start dateOct 2021

Last updatedMay 21, 2025

Condition

Chronic Lymphocytic Leukemia

Locations shown

Research Site

Fountain Valley, California

Research Site

Redlands, California

Research Site

Boca Raton, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions